FindTrial
Sign In

The Impact of Adjuvant Therapy on Survival in Stage I Invasive Lung Adenocarcinoma with High-Risk Pathological Factors: A Retrospective Cohort Study

The Impact of Adjuvant Therapy on Survival in Stage I Invasive Lung Adenocarcinoma with High-Risk Pathological Factors: A Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600115920
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Case group:not related

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age >=18 years old; 2.Postoperative pathology confirmed as stage I invasive lung adenocarcinoma; 3.At least one of the following high-risk pathological features: vascular invasion (+), containing micropapillary, solid components, complex glands or cribriform type, STAS (+), poorly differentiated tumor, pleural invasion (+).

Exclusion criteria

Exclusion criteria: 1.Undergoing unplanned surgery; 2.Having a history of previous malignant tumor; 3.Receiving neoadjuvant therapy; 4.Having missing key pathological data; 5.Death within 30 days after surgery.

Design outcomes

Primary

MeasureTime frame
Disease-free Survival;—

Secondary

MeasureTime frame
Overall Survival;—

Countries

China

Contacts

Public ContactJiandong Mei

West China Hospital, Sichuan University

jiandongmei@aliyun.com+86 189 8060 1762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026